Daina Graybosch
Stock Analyst at Leerink Partners
(0.09)
# 4,770
Out of 5,090 analysts
503
Total ratings
38.2%
Success rate
-7.9%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Reiterated: Buy | $17 → $31 | $17.61 | +76.04% | 3 | Oct 29, 2026 | |
| GILD Gilead Sciences | Rated: Hold | $127 → $129 | $170.68 | -24.42% | 30 | Oct 15, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $161 | $149.52 | +7.68% | 79 | Oct 12, 2026 | |
| CRBU Caribou Biosciences | Downgraded: Hold | $1 | $0.4232 | +136.29% | 1 | Oct 7, 2026 | |
| IPHA Innate Pharma | Upgraded: Buy | $2 → $4 | $1.46 | +173.97% | 33 | Aug 11, 2026 | |
| CGEN Compugen | Reiterated: Buy | $13 → $5 | $1.98 | +152.53% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $49 → $47 | $18.19 | +158.38% | 25 | Apr 20, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $88.17 | +28.16% | 67 | Feb 2, 2026 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $1.47 | +36.05% | 26 | Nov 17, 2025 | |
| SMMT Summit Therapeutics | Reiterated: Sell | n/a | $16.03 | n/a | 7 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $1.20 | n/a | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $6 | $6.59 | n/a | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $7 | $2.08 | n/a | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.9861 | n/a | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $8.03 | n/a | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.51 | n/a | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.56 | n/a | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.000001 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $3.58 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $74.68 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 | $38.87 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.79 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.000001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $3.38 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 35.00 | CHF 2.89 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €84.78 → €89.24 | €151.30 | n/a | 3 | Aug 25, 2020 |
Replimune Group
Oct 29, 2026
Reiterated: Buy
Price Target: $17 → $31
Current: $17.61
Upside: +76.04%
Gilead Sciences
Oct 15, 2026
Rated: Hold
Price Target: $127 → $129
Current: $170.68
Upside: -24.42%
Merck & Co.
Oct 12, 2026
Reiterated: Buy
Price Target: $161
Current: $149.52
Upside: +7.68%
Caribou Biosciences
Oct 7, 2026
Downgraded: Hold
Price Target: $1
Current: $0.4232
Upside: +136.29%
Innate Pharma
Aug 11, 2026
Upgraded: Buy
Price Target: $2 → $4
Current: $1.46
Upside: +173.97%
Compugen
May 21, 2026
Reiterated: Buy
Price Target: $13 → $5
Current: $1.98
Upside: +152.53%
Arcus Biosciences
Apr 20, 2026
Reiterated: Buy
Price Target: $49 → $47
Current: $18.19
Upside: +158.38%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $88.17
Upside: +28.16%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $1.47
Upside: +36.05%
Summit Therapeutics
Oct 22, 2025
Reiterated: Sell
Price Target: n/a
Current: $16.03
Upside: n/a
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $1.20
Upside: n/a
Sep 4, 2025
Reiterated: Hold
Price Target: $20 → $6
Current: $6.59
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $7
Current: $2.08
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.9861
Upside: n/a
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $8.03
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $2.51
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $8
Current: $1.56
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.000001
Upside: n/a
Aug 28, 2024
Reiterated: Hold
Price Target: $6
Current: $3.58
Upside: n/a
Dec 11, 2023
Reiterated: Buy
Price Target: n/a
Current: $74.68
Upside: n/a
Sep 15, 2023
Reiterated: Hold
Price Target: $1.5
Current: $38.87
Upside: n/a
Jun 5, 2023
Reiterated: Buy
Price Target: n/a
Current: $3.79
Upside: n/a
Apr 27, 2022
Reiterated: Buy
Price Target: $5
Current: $0.000001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $3.38
Upside: n/a
Apr 6, 2021
Reiterated: Buy
Price Target: CHF 35.00
Current: CHF 2.89
Upside: n/a
Aug 25, 2020
Reiterated: Buy
Price Target: €84.78 → €89.24
Current: €151.30
Upside: n/a